Acute Hypoxemic Respiratory Failure, COVID-19
Conditions
Keywords
COVID-19, acute hypoxemic respiratory failure (AHRF)
Brief summary
The main manifestation of COVID-19 is acute hypoxemic respiratory failure (AHRF). In patients with AHRF, the need for invasive mechanical ventilation is associated with high mortality. Two hypotheses will be tested in this study. The first hypothesis is the benefit of corticosteroid therapy on severe COVID-19 infection admitted in ICU in terms of survival. The second hypothesis is that, in the subset of patients free of mechanical ventilation at admission, either Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) allows to reduce intubation rate safely during COVID-19 related acute hypoxemic respiratory failure.
Detailed description
The main manifestation of COVID-19 is acute hypoxemic respiratory failure (AHRF). In patients with AHRF, the need for invasive mechanical ventilation is associated with high mortality. Two hypotheses will be tested in this study. The first hypothesis is the benefit of corticosteroid therapy on severe COVID-19 infection admitted in ICU in terms of survival. The second hypothesis is that, in the subset of patients free of mechanical ventilation at admission, either Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) allows to reduce intubation rate safely during COVID-19 related acute hypoxemic respiratory failure. The main objective is to assess the impact of dexamethasone on overall mortality at day-60 after randomization in patients admitted in ICU for severe COVID-19 infection. In non mechanical ventilation (MV) patients, the additional objective is to assess whether oxygen support based on either HFNO or CPAP modality in COVID-19 related AHRF reduces the need for mechanical ventilation at day-28. An ancillary study CACAO (COVIDICUS air contamination) will be performed in 4 centers aiming at assessing the environmental contamination by SARS-CoV-2 according to the oxygen support modality. Additional funding will be searched for these analyses (submitted for ANR call). A metanalysis on individual data will be performed using patients enrolled in the 3 PHRC flash exploring the activity of corticosteroids.
Interventions
Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
DRUGplacebo
Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
PROCEDUREconventional oxygen
The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
PROCEDURECPAP
Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
PROCEDUREHFNO
TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
PROCEDUREmechanical ventilation
The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The masking label is available only for the treatment assignation
Intervention model description
In non-mechanically ventilated patients, a 2x2 factorial design will be used to assess the two interventions, separately.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Admitted to ICU within 48 hours 3. Confirmed or highly suspected COVID-19 infection 4. Acute hypoxemic respiratory failure (PaO2 \<70 mmHg or SpO2\<90% on room air or tachypnea\>30/min or labored breathing or respiratory distress; need for oxygen flow \>=6L/min) 5. Any treatment intended to treat the SARS-CoV-2 infection in the absence of contraindications (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). Non-inclusion Criteria: 1. Moribund status 2. Pregnancy or breastfeeding 3. Long term corticotherapy at a dose of 0.5mg/kg/j or higher 4. Active and untreated bacterial, fungal or parasitic infection 5. Not Written informed consent from the patient or a legal representative if appropriate . If absence a legal representative the patient may be included in emergency procedure 6. hypersensitivity to dexamethasone or to any of the excipients 7. Not Affiliation to the French social security
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time-to-death from all causes | day-60 | The time-to-death from all causes within the first 60 days after randomization. |
| The time to need for mechanical ventilation (MV) | day-28. | the time to need for mechanical ventilation (MV), as defined by any of the 3 criteria for intubation within the first 28 days after randomization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of days alive without mechanical ventilation | day-28 | To compare the exposition to mechanical ventilation |
| Measure of SOFA score | day-1 to day 3, day 7, day 10, day 21, day 28 | Changes in SOFA (Sepsis-related Organ Failure Assessment) score. (min = 0 for normal status max = 24 for worse status) |
| Number of days alive without renal replacement therapy | day-28 | to compare the exposition to renal replacement therapy |
| Lengths of ICU-stay | day-60 | To compare the lengths of ICU |
| The viral load in the respiratory tract | day-10 | The cycle threshold for SARS-CoV-2 PCR at baseline, day 7+/-1 and day 10 +/- in samples of the same origin (preferably subglottic i.e. bronchoalveolar lavage or tracheal aspiration, otherwise nasopharyngeal swab) |
| Number of patients with severe hypoxemia, | day 60 | Proportion of patients with severe hypoxemia, which is defined as an oxygen saturation of less than 80% during the same interval during the interval between induction and 2 minutes after tracheal intubation |
| Proportion of patients with cardiac arrest within 1 hour after intubation | day 60 | Proportion of patients with cardiac arrest within 1 hour after intubation |
| Overall survival | day 60 | To compare Overall survival after randomization |
| Lengths of hospital-stay | day-60 | To compare the lengths of hospital-stay |
| Number of patient with at least one episode of healthcare-associated infections | day-28 | Proportion of patients with at least one episode of any healthcare-associated infection between randomization and D28 |
Countries
France
Outcome results
None listed